Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Comparing Common Therapies in Polycythemia Vera (PV): A Disproportionality Analysis in the FDA Adverse Event Reporting System (FAERS) Database

Frank Snopek, Ali Seddighzadeh, Megan Flynn, Ling-Yu Cai, Esther Chen, Weichung Joe Shih, Albert Qin, Raymond W Urbanski

Blood (2023) 142 (Supplement 1): 6436.

https://doi.org/10.1182/blood-2023-190344

Published: 2023

Journal Articles

A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

John Mascarenhas, Tsewang Tashi, Firas El Chaer, Victor Priego, Oleh Zagrijtschuk, Albert Qin, Jewell Jessup, Craig Zimmerman, Ray Urbanski, Lucia Masarova

Blood (2023) 142 (Supplement 1): 6444.

https://doi.org/10.1182/blood-2023-189912

Published: 2023

Journal Articles

Phase Ⅱ,Open-Label, Multicenter, Single-Arm Study Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea(HU)

Blood (2022) 140 (Supplement 1): 6858–6859.

https://doi.org/10.1182/blood-2022-165789

Published: 2022

Journal Articles

A Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

John Mascarenhas, Oleh Zagrijtschuk, Craig Zimmerman, Albert Qin, Raymond W Urbanski

Blood (2022) 140 (Supplement 1): 6748–6749.

https://doi.org/10.1182/blood-2022-162693

Published: 2022

Journal Articles

Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia

Ruben A. Mesa, Norio Komatsu, Harinder Gill, Jie Jin, Sung-Eun Lee, Hsin-An Hou, Toshiaki Sato, Albert Qin, Raymond Urbanski, Weichung Shih, Oleh Zagrijtschuk, Craig Zimmerman, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 1491.

https://doi.org/10.1182/blood-2021-147417

Published: 2021

Journal Articles

The Design of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea (HU)

Jie Jin, Lei Zhang, Su-Jiang Zhang, Suning Chen, Ming-hui Duan, Jingjing Zhang, Wei Wang, Warren Shen, Oleh Zagrijtschuk, Raymond Urbanski, Albert Qin, Zhijian Xiao

Blood (2021) 138 (Supplement 1): 4628.

https://doi.org/10.1182/blood-2021-146449

Published: 2021

Journal Articles

The Rationale, Design, and Baseline Characteristics of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Japanese Patients with Polycythemia Vera for Whom the Current Standard of Care Is Difficult to Apply

Keita Kirito, MD, Kazuya Shimoda, MD PhD, Katsuto Takenaka, MD PhD, Albert Qin, MD PhD, Oleh Zagrijtschuk, MD, Toshiaki Sato, MD PhD, Narihisa Miyachi, Hiroaki Kawase, Katsuya Yonezu, Norio Komatsu, MD PhD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-142504

Published: 2020

Journal Articles

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.

Asher Chanan-Khan, MD, Jeffrey Wolf, MD, Mecide Gharibo, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Debbie Manfredi, Kelvin P. Lee, MD, Kena C Miller, NP, Robin Guild, Sybil Zildjian, MPH, Albert Qin, MD, Ph.D., James O'Leary, MD, Robert Vescio, MD

Blood (2009) 114 (22): 2883.

https://doi.org/10.1182/blood.V114.22.2883.2883

Published: 2009

Journal Articles

Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma

Asher Alban Chanan-Khan, MD, Mecide Gharibo, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Kenneth C Anderson, MD, Dawn DePaolo, Kelvin P. Lee, MD, Kena Miller, RN, MSN, FNP, Robin Guild, Sybil Zildjian, Albert Qin

Blood (2008) 112 (11): 3689.

https://doi.org/10.1182/blood.V112.11.3689.3689

Published: 2008

NARROW

Comparing Common Therapies in Polycythemia Vera (PV): A Disproportionality Analysis in the FDA Adverse Event Reporting System (FAERS) Database

A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

Phase Ⅱ,Open-Label, Multicenter, Single-Arm Study Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea(HU)

A Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia

The Design of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea (HU)

The Rationale, Design, and Baseline Characteristics of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Japanese Patients with Polycythemia Vera for Whom the Current Standard of Care Is Difficult to Apply

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.

Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only